Table 1.

γHV-68-specific CD8⁺ T cells in the peritoneal cavity and spleen 7 days after i.p. challenge of HV-68-infected mice with recombinant vaccinia viruses

Immunization	Tetramer		Peptide stimulation
	p56Db	p79Kb	p56	p79
PEL
vacc-LCMVb	1.4  ± 0.9	1.7  ± 0.8	0.3  ± 0.2	1.4  ± 0.6
vacc-p56	24.9  ± 6.9*	0.8  ± 0.3*	38.4  ± 8.9*	0.9  ± 0.1
vacc-p79	1.1  ± 0.4*	13.7  ± 2.6	0.2  ± 0.3	38.5  ± 15.4
Spleen
vacc-LCMVb	1.1  ± 0.4	1.6  ± 0.1	0.35  ± 0.2	1.2  ± 0.1
vacc-p56	15.2  ± 2.1	1.5  ± 0.2	15.3  ± 1	1  ± 0.1
vacc-p79	0.9  ± 0.3	12.4  ± 6	0.2  ± 0.2	17.1  ± 9.2

The B6 (I-A^b+/+) mice had been infected i.n. with 600 pfu of γHV-68 4 wk prior to i.p. challenge with 3 × 10⁷ pfu of the recombinant vaccinia viruses. The CD8⁺ T cells in the PEL and spleen populations were either stained with the tetramers or were restimulated for 5 h in vitro before analyzing for intracellular IFN-γ. Each value is the mean ± SD for the percent in the CD8⁺ set in three separate experiments. The results for those that were given vacc-LCMV^b are equivalent to the virus-specific CD8⁺ T cell frequencies found normally in γHV-68-infected I-A^b+/+ mice (12, 14). 

^*The CD8⁺ T cells in the PEL (and spleen) samples recovered from mice that had never been exposed to γHV-68 were 2.9% (2.1%) p56D^b+ and 4.5% (2.2%) IFN-γ⁺ at 7 days after vacc-p56 infection, while <1% in either site were shown to be p79-specific after the comparable i.p. challenge with vacc-p79.